Zinc protoporphyrin levels in COVID-19 are indicative of iron deficiency and potential predictor of disease severity

PLoS One. 2022 Feb 3;17(2):e0262487. doi: 10.1371/journal.pone.0262487. eCollection 2022.

Abstract

Background: Coronavirus disease (COVID-19) has a severe impact on all aspects of patient care. Among the numerous biomarkers of potential validity for diagnostic and clinical management of COVID-19 are biomarkers at the interface of iron metabolism and inflammation.

Methods: The follow-up study included 54 hospitalized patients with laboratory-confirmed COVID-19 with a moderate and severe/critical form of the disease. Iron deficiency specific biomarkers such as iron, ferritin, transferrin receptor, hepcidin, and zinc protoporphyrin (ZnPP) as well as relevant markers of inflammation were evaluated twice: in the first five days when the patient was admitted to the hospital and during five to 15 days; and their validity to diagnose iron deficiency was further assessed. The regression and Receiver Operating Characteristics (ROC) analyses were performed to evaluate the prognosis and determine the probability for predicting the severity of the disease in the first five days of COVID-19.

Results: Based on hemoglobin values, anemia was observed in 21 of 54 patients. Of all iron deficiency anemia-related markers, only ZnPP was significantly elevated (P<0.001) in the anemic group. When patients were grouped according to the severity of disease, slight differences in hemoglobin or other anemia-related parameters could be observed. However, the levels of ZnPP were significantly increased in the severely ill group of patients. The ratio of ZnPP to lymphocyte count (ZnPP/L) had a discrimination power stronger than the neutrophil to lymphocyte count ratio (N/L) to determine disease severity. Additionally, only two markers were independently associated with the severity of COVID-19 in logistic regression analysis; D-dimer (OR (5.606)(95% CI 1.019-30.867)) and ZnPP/L ratio (OR (74.313) (95% CI 1.081-5108.103)).

Conclusions: For the first time ZnPP in COVID-19 patients were reported in this study. Among all iron-related markers tested, ZnPP was the only one that was associated with anemia as based on hemoglobin. The increase in ZnPP might indicate that the underlying cause of anemia in COVID-19 patients is not only due to the inflammation but also of nutritional origin. Additionally, the ZnPP/L ratio might be a valid prognostic marker for the severity of COVID-19.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anemia, Iron-Deficiency / blood*
  • Anemia, Iron-Deficiency / complications*
  • Anemia, Iron-Deficiency / epidemiology
  • Biomarkers / blood
  • COVID-19 / blood*
  • COVID-19 / complications*
  • COVID-19 / epidemiology
  • COVID-19 / virology
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Follow-Up Studies
  • Hemoglobins / analysis
  • Humans
  • Logistic Models
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Patient Admission
  • Prognosis
  • Protoporphyrins / blood*
  • SARS-CoV-2 / genetics*
  • Severity of Illness Index*
  • Turkey / epidemiology

Substances

  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • Hemoglobins
  • Protoporphyrins
  • fibrin fragment D
  • zinc protoporphyrin

Grants and funding

This work is supported by Acıbadem Labmed Clinical Laboratories and funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 491466077. There was no additional external funding received for this study.